Talactoferrin alfa
- Generic Name
- Talactoferrin alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308240-58-6
- Unique Ingredient Identifier
- 7A055A9QRR
- Background
Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
- Indication
Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Agennix
- Target Recruit Count
- 1280
- Registration Number
- NCT01273779
- Locations
- 🇨🇦
Royal Jubilee Hospital, Victoria, British Columbia, Canada
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Methodist Research Institute, Indianapolis, Indiana, United States
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- Agennix
- Target Recruit Count
- 190
- Registration Number
- NCT00630656
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Kingston General Hospital, Kingston, Ontario, Canada
🇺🇸University of Pittsburgh Medical Center Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.